To hear about similar clinical trials, please enter your email below

Trial Title: Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers

NCT ID: NCT01675258

Condition: Gastric Cancer
Colorectal Cancer and Pre-cancer Polyps
Pancreatic Cancer

Conditions: Official terms:
Pancreatic Neoplasms
Polyps

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Cross-Sectional

Intervention:

Intervention type: Other
Intervention name: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
Arm group label: Control
Arm group label: Study

Other name: Salivary Analysis

Summary: Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers are mostly diagnosed only at later stages of the disease's course through histoimmune staining and molecular biology processes on the tissues biopsied from the gastrointestinal system under invasive diagnostic procedures of colonoscopy. Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers. The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.

Criteria for eligibility:

Study pop:
Patients identified with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Has not yet started treatment for the identified cancer Exclusion Criteria: - medically compromised patients - congenital syndromes - being treated with radiotherapy or chemotherapy.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Hadassah Medical Organization

Address:
City: Jerusalem
Country: Israel

Contact:
Last name: Hadas Lemberg, PhD

Phone: 0097226777572
Email: lhadas@hadassah.org.il

Investigator:
Last name: Moti Moskovitz, DMD, PhD
Email: Principal Investigator

Start date: September 2012

Lead sponsor:
Agency: Hadassah Medical Organization
Agency class: Other

Source: Hadassah Medical Organization

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01675258

Login to your account

Did you forget your password?